MEGGLE Excipients & Technology is a global leader in manufacturing lactose for the pharmaceutical industry. Supporting supply chain security with manufacturing facilities in Europe and North America, MEGGLE offers a broad product portfolio of lactose excipients, co-processed technologies and excipient contract manufacturing.
MEGGLE is a pioneer in co-processing technologies that allow simple, robust formulation development and manufacture. Through co-processing, MEGGLE developed highly functional excipients possessing unique qualities for directly compressible immediate and sustained release pharmaceutical solid dosage forms.
MEGGLE Excipients & Technologies serves the pharmaceutical and biotechnology markets with a global network of offices and authorized agents. As an innovator in co-processed technology, MEGGLE also provides contract manufacturing services to several other global excipient companies.
Our broad portfolio of products, multiple manufacturing locations, technical centers in major markets, and innovative technologies, make MEGGLE the preferred supplier and valued partner for pharmaceutical product manufacturers.
MEGGLE Excipients & Technologies products:
MEGGLE Excipients & Technologies Services:
Contact Details :
MEGGLE Excipient & Technology
www.meggle-pharma.com service.pharma@meggle.de
Transformations in Drug Development for Cell and Gene Therapies
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Advancing Clinical Trials with Spectral Flow Cytometry: A Conversation with Kevin Lang
March 28th 2025As a recognized leader in immunophenotyping for clinical trials, Kevin Lang from PPD discusses how spectral flow cytometry is transforming drug development, particularly in cell and gene therapies like CAR-T. He also dives into his award-winning research, including his 2024 WRIB Poster Award-winning work, and his insights from presenting at AAPS PharmSci360.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.